EUROELSO ASSOCIATES
The objects of the charity are to advance and promote the relief of sickness across Europe through the development and evaluation of novel therapies for support of failing organ systems; maintaining a registry of such novel therapies; supporting clinical research and providing educational programs for medical professionals and lay communities including organising a scientific symposium each year.
Financial health, per its FY2025 accounts
The accounts state that the charity reported a net expenditure of £1,080 for the year ended 30 November 2025, resulting in total unrestricted funds of £611,964. The trustees confirm that the charity has adequate resources to continue in operational existence for the foreseeable future, adopting the going concern basis. The charity maintains a policy to hold unrestricted income at an appropriate level to meet charitable and governance expenditure.
What the accounts disclose
“It is the policy of the charity to maintain unrestricted income funds at an appropriate level to ensure that charitable and governance expenditure can be met out of undistributed income.” — page 6
Trustees
- Alain Combes
- JON SMITH
- Simon Finney
- Thomas Muller
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 30/11/2025 | £139k | £140k |
| 30/11/2024 | £139k | £77k |
| 30/11/2023 | £42k | £116k |
| 30/11/2022 | £57k | £130k |
| 30/11/2021 | £22k | £63k |
Common questions
Is EUROELSO ASSOCIATES financially healthy?
Per its FY2025 accounts: The accounts state that the charity reported a net expenditure of £1,080 for the year ended 30 November 2025, resulting in total unrestricted funds of £611,964. The trustees confirm that the charity has adequate resources to continue in operational existence for the foreseeable future, adopting the going concern basis. The charity maintains a policy to hold unrestricted income at an appropriate level to meet charitable and governance expenditure. Its FY2025 accounts were independently examined.